Ona Therapeutics moves to Phase I with ADC for advanced cancers

Ona Therapeutics has progressed to a Phase Ia clinical development of its lead first-in-class antibody-drug conjugate (ADC), ONA-255, for the treatment of advanced cancers. The company says that more than half of the patients planned for th…

Summary from DDW Drug Discovery World.

Coverage 1 article · 1 outlet

1. DDW Drug Discovery World 3h ago
   Ona Therapeutics moves to Phase I with ADC for advanced cancers ↗